Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

P. Conte; A. Frassoldati; G. Bisagni; A.A. Brandes; M. Donadio; O. Garrone; F. Piacentini; L. Cavanna; F. Giotta; M. Aieta; V. Gebbia; A. Molino; A. Musolino; A. Ferro; R. Maltoni; S. Danese; C. Zamagni; A. Rimanti; K. Cagossi; A. Russo; P. Pronzato; F. Giovanardi; G. Moretti; L. Lombardo; A. Schirone; A. Beano; L. Amaducci; E.A. Bajardi; R. Vicini; S. Balduzzi; R. D'Amico; V. Guarneri; Reader study level-I and level-II Groups

doi:10.1093/annonc/mdy414

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

P. Conte, A. Frassoldati, G. Bisagni, A.A. Brandes, M. Donadio, O. Garrone, F. Piacentini, L. Cavanna, F. Giotta, M. Aieta, V. Gebbia, A. Molino, A. Musolino, A. Ferro, R. Maltoni, S. Danese, C. Zamagni, A. Rimanti, K. Cagossi, A. RussoP. Pronzato, F. Giovanardi, G. Moretti, L. Lombardo, A. Schirone, A. Beano, L. Amaducci, E.A. Bajardi, R. Vicini, S. Balduzzi, R. D'Amico, V. Guarneri, Reader study level-I and level-II Groups

Research output: Contribution to journal › Article › peer-review

Original language	Italian
Pages (from-to)	2328-2333
Number of pages	6
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
Issue number	12
DOIs	https://doi.org/10.1093/annonc/mdy414
Publication status	Published - 2018

Access to Document

10.1093/annonc/mdy414

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059263988&doi=10.1093%2fannonc%2fmdy414&partnerID=40&md5=cecadc0f1267f829d581be006793ef95

Cite this

Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., ... Groups, R. S. L-I. A. L-II. (2018). Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. Annals of oncology : official journal of the European Society for Medical Oncology, 29(12), 2328-2333. https://doi.org/10.1093/annonc/mdy414

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. / Conte, P.; Frassoldati, A.; Bisagni, G. et al.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, No. 12, 2018, p. 2328-2333.

Research output: Contribution to journal › Article › peer-review

Conte, P, Frassoldati, A, Bisagni, G, Brandes, AA, Donadio, M, Garrone, O, Piacentini, F, Cavanna, L, Giotta, F , Aieta, M, Gebbia, V, Molino, A, Musolino, A, Ferro, A, Maltoni, R, Danese, S, Zamagni, C, Rimanti, A, Cagossi, K, Russo, A, Pronzato, P, Giovanardi, F, Moretti, G, Lombardo, L, Schirone, A, Beano, A, Amaducci, L, Bajardi, EA, Vicini, R, Balduzzi, S, D'Amico, R, Guarneri, V & Groups, RSL-IAL-II 2018, 'Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, no. 12, pp. 2328-2333. https://doi.org/10.1093/annonc/mdy414

@article{d0f16b07faa243e3b0a3472ed614f1bd,

title = "Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡",

author = "P. Conte and A. Frassoldati and G. Bisagni and A.A. Brandes and M. Donadio and O. Garrone and F. Piacentini and L. Cavanna and F. Giotta and M. Aieta and V. Gebbia and A. Molino and A. Musolino and A. Ferro and R. Maltoni and S. Danese and C. Zamagni and A. Rimanti and K. Cagossi and A. Russo and P. Pronzato and F. Giovanardi and G. Moretti and L. Lombardo and A. Schirone and A. Beano and L. Amaducci and E.A. Bajardi and R. Vicini and S. Balduzzi and R. D'Amico and V. Guarneri and Groups, {Reader study level-I and level-II}",

note = "Export Date: 1 February 2019",

year = "2018",

doi = "10.1093/annonc/mdy414",

language = "Italian",

volume = "29",

pages = "2328--2333",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "12",

}

TY - JOUR

T1 - Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

AU - Conte, P.

AU - Frassoldati, A.

AU - Bisagni, G.

AU - Brandes, A.A.

AU - Donadio, M.

AU - Garrone, O.

AU - Piacentini, F.

AU - Cavanna, L.

AU - Giotta, F.

AU - Aieta, M.

AU - Gebbia, V.

AU - Molino, A.

AU - Musolino, A.

AU - Ferro, A.

AU - Maltoni, R.

AU - Danese, S.

AU - Zamagni, C.

AU - Rimanti, A.

AU - Cagossi, K.

AU - Russo, A.

AU - Pronzato, P.

AU - Giovanardi, F.

AU - Moretti, G.

AU - Lombardo, L.

AU - Schirone, A.

AU - Beano, A.

AU - Amaducci, L.

AU - Bajardi, E.A.

AU - Vicini, R.

AU - Balduzzi, S.

AU - D'Amico, R.

AU - Guarneri, V.

AU - Groups, Reader study level-I and level-II

N1 - Export Date: 1 February 2019

PY - 2018

Y1 - 2018

U2 - 10.1093/annonc/mdy414

DO - 10.1093/annonc/mdy414

M3 - Articolo

VL - 29

SP - 2328

EP - 2333

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -